Atria Investments LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 234,610 shares of the biopharmaceutical company’s stock after acquiring an additional 25,728 shares during the quarter. Atria Investments LLC’s holdings in Pfizer were worth $8,498,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the stock. Hexavest Inc. grew its holdings in Pfizer by 1.9% in the 4th quarter. Hexavest Inc. now owns 6,927,838 shares of the biopharmaceutical company’s stock valued at $250,926,000 after buying an additional 129,181 shares in the last quarter. Daiwa SB Investments Ltd. grew its holdings in Pfizer by 25.2% in the 4th quarter. Daiwa SB Investments Ltd. now owns 8,540 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 1,720 shares in the last quarter. Acropolis Investment Management LLC grew its holdings in Pfizer by 333.4% in the 4th quarter. Acropolis Investment Management LLC now owns 9,032 shares of the biopharmaceutical company’s stock valued at $327,000 after buying an additional 6,948 shares in the last quarter. Sawyer & Company Inc acquired a new position in Pfizer in the 4th quarter valued at $1,078,000. Finally, Rockland Trust Co. grew its holdings in Pfizer by 2.9% in the 4th quarter. Rockland Trust Co. now owns 187,127 shares of the biopharmaceutical company’s stock valued at $6,778,000 after buying an additional 5,204 shares in the last quarter. 71.41% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (PFE) opened at $36.61 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43. The firm has a market capitalization of $217,930.00, a price-to-earnings ratio of 20.92, a P/E/G ratio of 2.07 and a beta of 0.91.
Pfizer announced that its Board of Directors has authorized a stock repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a dividend of $0.34 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.71%. The ex-dividend date of this dividend was Thursday, February 1st. Pfizer’s dividend payout ratio is currently 77.71%.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at $36,790. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 185,464 shares of company stock valued at $6,767,939. 0.06% of the stock is owned by corporate insiders.
PFE has been the topic of a number of research reports. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Friday, December 15th. UBS Group set a $40.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Deutsche Bank set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price for the company in a research report on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 target price on Pfizer and gave the company a “buy” rating in a research report on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $39.40.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.